Literature DB >> 9659225

Peritoneal macrophages play an important role in eliminating human cells from severe combined immunodeficient mice transplanted with human peripheral blood lymphocytes.

S Shibata1, T Asano, A Noguchi, M Naito, A Ogura, K Doi.   

Abstract

To elucidate the mechanism of human cell elimination from severe combined immunodeficient (SCID) mice transplanted with human peripheral blood lymphocytes (hu-PBL-SCID mice), we explored the immunocytes in the peritoneal cavity in SCID mice where human PBL were transferred. When the phenotype of peritoneal exudate cells (PEC) was compared by flow cytometry among three congenic strains of SCID mice that differ in their acceptability for human PBL, the PEC in NOD-scid mice, which exhibit the highest acceptability, contained the smallest number of F4/80lo/-Mac-1(+)-activated macrophages. Moreover, the proportions of natural killer cells in PEC of the three strains of SCID mice were not always correlated with the acceptability. These findings suggest the possibility that peritoneal macrophages eliminate human cells in hu-PBL-SCID mice. To verify this hypothesis, we evaluated the engraftment of human PBL into SCID mice that were treated with liposome-encapsulated dichloromethylene diphosphonate, which selectively depletes macrophages by inducing apoptosis, or 8-aminoguanidine hemisulphate salt, an inhibitor of inducible nitric oxide synthase of macrophages. As a result, both of these regimens improved engraftment of human PBL, indicating that peritoneal macrophages take part in human cell elimination in the peritoneal cavity of hu-PBL-SCID mice and that it is mediated, at least in part, by direct macrophage cytotoxicity utilizing nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659225      PMCID: PMC1364131          DOI: 10.1046/j.1365-2567.1998.00458.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

Review 1.  The basis for the immunoregulatory role of macrophages and other accessory cells.

Authors:  E R Unanue; P M Allen
Journal:  Science       Date:  1987-05-01       Impact factor: 47.728

2.  F4/80, a monoclonal antibody directed specifically against the mouse macrophage.

Authors:  J M Austyn; S Gordon
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

3.  A severe combined immunodeficiency mutation in the mouse.

Authors:  G C Bosma; R P Custer; M J Bosma
Journal:  Nature       Date:  1983-02-10       Impact factor: 49.962

4.  Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice.

Authors:  D L Greiner; L D Shultz; J Yates; M C Appel; G Perdrizet; R M Hesselton; I Schweitzer; W G Beamer; K L Shultz; S C Pelsue
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

5.  Limitations of the severe combined immunodeficiency (SCID) mouse model for study of human B-cell responses.

Authors:  R Somasundaram; L Jacob; K Adachi; R Class; S Scheck; H Maruyama; D Herlyn
Journal:  Scand J Immunol       Date:  1995-04       Impact factor: 3.487

6.  Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid).

Authors:  K Dorshkind; S B Pollack; M J Bosma; R A Phillips
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

7.  Circulation of human hematopoietic cells in severe combined immunodeficient mice after Cl2MDP-liposome-mediated macrophage depletion.

Authors:  C C Fraser; B P Chen; S Webb; N van Rooijen; G Kraal
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

8.  High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice.

Authors:  R M Hesselton; D L Greiner; J P Mordes; T V Rajan; J L Sullivan; L D Shultz
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

Review 9.  The human immune system in hu-PBL-SCID mice.

Authors:  M Tary-Lehmann; A Saxon; P V Lehmann
Journal:  Immunol Today       Date:  1995-11

10.  Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection.

Authors:  W J Murphy; V Kumar; M Bennett
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

View more
  6 in total

1.  Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells.

Authors:  C Gysemans; M Waer; J Laureys; J Depovere; D Pipeleers; R Bouillon; C Mathieu
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Mouse strain and conditioning regimen determine survival and function of human leucocytes in immunodeficient mice.

Authors:  K G Tournoy; S Depraetere; R A Pauwels; G G Leroux-Roels
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

3.  Anti-inflammatory and anti-insulin resistance activities of aqueous extract from Anoectochilus burmannicus.

Authors:  Phatcharaporn Budluang; Pornsiri Pitchakarn; Pisamai Ting; Piya Temviriyanukul; Ariyaphong Wongnoppawich; Arisa Imsumran
Journal:  Food Sci Nutr       Date:  2016-08-26       Impact factor: 2.863

4.  Intestinal epithelial glucocorticoid receptor promotes chronic inflammation-associated colorectal cancer.

Authors:  Shuang Tang; Zhan Zhang; Robert H Oakley; Wenling Li; Weijing He; Xiaojiang Xu; Ming Ji; Qing Xu; Liang Chen; Alicia S Wellman; Qingguo Li; Leping Li; Jian-Liang Li; Xinxiang Li; John A Cidlowski; Xiaoling Li
Journal:  JCI Insight       Date:  2021-12-22

Review 5.  Mouse models with human immunity and their application in biomedical research.

Authors:  Baojun Zhang; Ziyuan Duan; Yong Zhao
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

6.  Human muscle-derived stem/progenitor cells promote functional murine peripheral nerve regeneration.

Authors:  Mitra Lavasani; Seth D Thompson; Jonathan B Pollett; Arvydas Usas; Aiping Lu; Donna B Stolz; Katherine A Clark; Bin Sun; Bruno Péault; Johnny Huard
Journal:  J Clin Invest       Date:  2014-03-18       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.